Incyclix Bio has raised an additional $5 million in Series B financing to support its treatment for advanced and resistant cancers. 

The cell cycle control company raised the funds from new investor Hatteras Venture Partners, which will help advance Incyclix Bio’s lead compound INX-315. The compound is a novel, potent and selective CDK2 inhibitor for the treatment of advanced and metastatic breast and ovarian cancer.  

“We are encouraged by Hatteras’s strong enthusiasm for our CDK2 programme and their support in advancing INX-315 toward meaningful clinical outcomes,” said Patrick Roberts, Chief Executive Officer and Co-Founder of Incyclix Bio. 

As part of the financing, Hatteras partner Kseniya Simpson will join the company’s board of directors and Hatteras general partner Christy Shaffer will join as a board observer. 

“CDK2 inhibition represents an exciting opportunity to address unmet need that remains in breast and ovarian cancer treatment,” Simpson added. 

“We believe in Incyclix’s highly experienced team and their capabilities to bring a best-in-class treatment option to patients with advanced and resistant cancer.”